Condition

Immunoglobulin A Nephropathy clinical trials and research

• 8Clinical trials
• 18Countries

Newest Immunoglobulin A Nephropathy clinical trials

All recruiting trials (8)

• Atrasentan for pediatric primary IgA nephropathy

  This study tests whether atrasentan can help children and teens with primary IgA nephropathy reduce protein in urine.

  Recruiting at 19 sites Phase 3 Novartis · Neptune City, New Jersey and 22 other locations · NCT07498335

• MIL116 for people with IgA nephropathy and healthy volunteers

  This trial will test whether subcutaneous MIL116, an anti‑APRIL antibody, is safe and how it behaves in the body in adults with IgA nephropathy and in healthy volunteers.

  Recruiting Phase 1/2 Beijing Mabworks Biotech Co., Ltd. · Beijing · NCT07375758

• Ravulizumab for children with IgA nephropathy or IgA vasculitis nephritis

  This trial will test whether intravenous ravulizumab is safe and changes disease markers in children aged 2 to under 18 with biopsy‑proven IgA nephropathy or IgA vasculitis nephritis.

  Recruiting at 13 sites Phase 3 Alexion Pharmaceuticals, Inc. · Palo Alto, California and 14 other locations · NCT07024563

• Mobile app to track symptoms and treatment in IgA nephropathy patients

  This study is testing a mobile app that helps people with IgA nephropathy track their symptoms and treatments to see how it affects their health and quality of life.

  Recruiting Novartis · Boston, Massachusetts · NCT06952426

• Iptacopan added to standard care to change kidney biopsy findings in adults with IgA nephropathy

  This will try iptacopan added to standard treatment for adults with biopsy-confirmed IgA nephropathy to see if it reduces mesangial complement (C3c) deposits and improves kidney biomarkers over 9 months.

  Recruiting at 19 sites Phase 2 Novartis · Birmingham, Alabama and 18 other locations · NCT06797518

• Treatment of pediatric kidney diseases with Sparsentan

  This study is testing if a new oral medication called Sparsentan can help children aged 1 to 18 with certain kidney diseases feel better and improve their condition over two years.

  Recruiting at 38 sites Phase 2 Travere Therapeutics, Inc. · Los Angeles, California and 46 other locations · NCT05003986

• Sparsentan for IgA Nephropathy: safety and activity in adults with incident IgAN and recurrent IgAN after transplant

  This trial tests whether sparsentan can be safely given and help kidney outcomes in adults with immunoglobulin A nephropathy, including people newly diagnosed who haven’t had ACEI/ARB therapy and people with recurrent IgAN after kidney transplant.

  Recruiting at 6 sites Phase 2 University of Leicester · Cambridge, England and 5 other locations · NCT04663204

• Personalized therapy for patients with IgA nephropathy

  This study is testing if personalized treatment plans can help people with IgA nephropathy feel better and lower their chances of serious kidney problems.

  Recruiting at 2 sites Phase 4 Fondazione Schena · Bari, BA and 1 other locations · NCT04662723

Related topics

Quick answers

How many Immunoglobulin A Nephropathy clinical trials are recruiting right now?

8, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 18 countries. The most sites are in United States (5 trials), China (3 trials), Italy (3 trials), Spain (3 trials), United Kingdom (2 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 3, Phase 3: 2, Phase 1/2: 1, Phase 4: 1. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →